Private Universitaet Witten/Herdecke gGmbH
- Address
- Alfred-Herrhausen-Strasse 50, 58448 Witten, Germany
Private Universität Witten/Herdecke - Pediatric Oncology & Hematology Research
Private Universität Witten/Herdecke serves as a key research site in the international AIEOP-BFM ALL 2017 collaborative network, focusing on advancing treatment protocols for acute lymphoblastic leukemia (ALL) in children and adolescents. The center contributes to groundbreaking studies evaluating novel therapeutic approaches tailored to different risk stratifications of pediatric ALL patients.
- Risk-stratified treatment protocols for precursor B-cell ALL (pB-ALL) including early high-risk, high-risk, and intermediate-risk patient populations
- Immunotherapy interventions with Blinatumomab for post-consolidation and post-reintensification treatment strategies
- Proteasome inhibitor therapy with Bortezomib for early high-risk patients with inadequate treatment response
- Optimized consolidation strategies for T-cell ALL (T-ALL) patients with early non-standard risk profiles
The research center's participation in this international collaborative protocol demonstrates its commitment to improving event-free survival and disease-free survival outcomes for pediatric leukemia patients through precision medicine approaches. By integrating targeted therapies with conventional chemotherapy regimens, the center contributes to establishing evidence-based treatment standards that account for genetic markers and minimal residual disease (MRD) response patterns.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Private Universitaet Witten/Herdecke gGmbH
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Reduced‑intensity post‑induction chemotherapy plus blinatumomab versus standard post‑induction therapy in pediatric standard‑risk B‑ALL (AIEOP‑BFM ALL 2025) | Universitaetsklinikum Schleswig-Holstein AöR | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Blinatumomab | 1 | Unknown | — | — |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.